FUNDAMENTALS · Fundamentals · CN Healthcare

Burning Rock Biotech (BNR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Burning Rock Biotech (BNR) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of

0M, trading at $9.31 on the NASDAQ. This SniperIQ fundamentals page covers Burning Rock Biotech's valuation, profitability (net margin -11.5%), revenue (¥540M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
0M
Net Margin-11.5%
Revenue (FY25)¥540M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Burning Rock Biotech's market cap?

Burning Rock Biotech (BNR) has a market capitalization of approximately

0M, trading at $9.31 on the NASDAQ. Market cap moves with the live share price.

What is Burning Rock Biotech's P/E ratio?

Burning Rock Biotech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Burning Rock Biotech?

Burning Rock Biotech runs a net profit margin of -11.5%, a gross margin of 74.6%, and an operating margin of -11.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Burning Rock Biotech generate?

Burning Rock Biotech reported revenue of ¥540M for fiscal year 2025, with net income of -¥55M and earnings per share (EPS) of -49.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Burning Rock Biotech pay a dividend?

Burning Rock Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Burning Rock Biotech financially healthy?

Burning Rock Biotech carries a debt-to-equity ratio of 0.10x and a current ratio of 3.05x, with a market beta of 1.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Burning Rock Biotech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Burning Rock Biotech (BNR) the key facts are: market cap

0M, revenue ¥540M, 52-week range 5.311-41.72. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Burning Rock Biotech's full fundamentals live

Get Burning Rock Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: BioVie (BIVI) fundamentals · Aptevo Therapeutics (APVO) fundamentals · Nexalin Technology (NXL) fundamentals · Cocrystal Pharma (COCP) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons